Skip to main content Skip to main content
VitalDecades logo VitalDecades
Weight and metabolism

GLP-1 medications compared: Wegovy, Zepbound and the pills

Michael Reeves Managing Editor
Updated 8 min read

We include products and services we think are useful. If you buy through links on this page, we may earn a commission. Here is how we pick.

Who made it and how it was checked

By Michael Reeves, Managing Editor. Researched and drafted with AI assistance, then edited by the editor named here. Fact-checked by Sarah Whitcomb, Senior Health Editor, . Its sources are listed on this page. No licensed clinician has reviewed it. How we source.

Report an error on this page

Two blue semaglutide injection pens on a pale surface.
Photo: Haberdoedas Photography / Pexels

For weight: Wegovy injection (weekly; 1.7 or 2.4 mg, or 7.2 mg Wegovy HD), Wegovy tablets (25 mg daily), Zepbound (weekly tirzepatide, 5 to 15 mg) and Foundayo (orforglipron pill, up to 17.2 mg daily). For type 2 diabetes: Ozempic, Mounjaro, Rybelsus. Label trial results range from about 7% (Saxenda) to 21% (Zepbound 15 mg) mean weight loss versus 2 to 4% on placebo. Self-pay prices run $149 to $699 a month.

Seven FDA-approved products now cover the GLP-1 class for weight or diabetes, from a daily injection approved in 2014 to a pill approved in April 2026. This is what each one is approved for, how it is taken, what its own label reports for weight loss, and what it costs at the manufacturer's self-pay price, every figure from the FDA label or the manufacturer's page. For the online programs that prescribe them, with each program's membership fee and medication price, see the program directory.

On this page

The products, in one table

Same active ingredient does not mean the same product: Ozempic and Wegovy are both semaglutide but differ in dose and approved use, as do Mounjaro and Zepbound (tirzepatide). Dates are the original FDA approvals from Drugs@FDA; results are the intention-to-treat figures in each label's clinical studies section (the label's numbers, not the company's adherence-based estimates, which run higher).

ProductMoleculeApproved forHow takenLabel result (mean weight loss vs placebo)
Wegovy injectionsemaglutideWeight (2021); cardiovascular risk reduction (2024); MASH (2025); 7.2 mg dose (Mar 2026)Weekly pen; 1.7 or 2.4 mg maintenance; 7.2 mg (Wegovy HD)2.4 mg: 14.9% vs 2.4% at 68 wk; 7.2 mg: 18.8% vs 3.9% at 72 wk
Wegovy tabletssemaglutideWeight and CV risk (Dec 22, 2025)Daily tablet; 25 mg maintenance after 1.5, 4, 9 mg steps13.6% vs 2.4% at 64 wk
ZepboundtirzepatideWeight (Nov 8, 2023); obstructive sleep apnea (Dec 2024)Weekly pen or vial; 5, 10 or 15 mg maintenance15 mg: 20.9% vs 3.1% at 72 wk (10 mg 19.5%; 5 mg 15.0%)
FoundayoorforglipronWeight (Apr 1, 2026)Daily tablet; 0.8 mg start, up to 17.2 mg17.2 mg: 11.1% vs 2.1% at 72 wk
Saxenda (and generics)liraglutideWeight (Dec 2014); first generic Aug 2025Daily injection; 3 mg7.4% vs 3.0% at 56 wk
OzempicsemaglutideType 2 diabetes (2017), plus CV and kidney outcomesWeekly pen; 0.5, 1 or 2 mgNot approved for weight; prescribed off-label
MounjarotirzepatideType 2 diabetes (May 2022), adults and children 10+Weekly pen or vial; up to 15 mgNot approved for weight; prescribed off-label
Rybelsus / Ozempic tabletssemaglutideType 2 diabetes (2019)Daily tabletNot approved for weight

How to read the trial numbers

The figures above come from each label's own tables (Wegovy Studies 2, 7 and 8; Zepbound Study 1; Foundayo Trials 1 and 2; Saxenda Study 1). They are averages for everyone randomized, including people who stopped early. Manufacturers also publish higher figures for people who stayed on treatment: Novo's release quotes about 21% for Wegovy HD and 16.6% for the pill, and Lilly's quotes 12.4% for Foundayo; those are the same trials measured a different way. Trials also differ in length (56 to 72 weeks) and in who enrolled, so a difference of a few points between two products is not a head-to-head result.

What every label says about risk

Each product carries a boxed warning: in rodents, GLP-1 receptor agonists cause thyroid C-cell tumors, and whether they do so in humans is unknown, so all are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Foundayo's boxed warning notes that orforglipron itself did not produce rodent tumors but carries the class warning. The labels also warn about pancreatitis, gallbladder disease, hypoglycemia with insulin or sulfonylureas, and kidney injury from dehydration; read the one that applies to you.

What they cost without insurance, August 2026

Manufacturer self-pay prices, from the NovoCare and LillyDirect price pages read on 2026-08-19: Wegovy tablets $149 (1.5 mg; 4 mg at $149 until August 31, 2026, then $199) and $299 (9 and 25 mg); Wegovy pen $199 a month for the first two months of 0.25 or 0.5 mg for new patients, then $349 for all doses through 2.4 mg, and $399 for Wegovy HD 7.2 mg; Zepbound $299 (2.5 mg), $399 (5 mg), and $449 for 7.5 to 15 mg if you refill within 45 days, otherwise $499 to $699; Foundayo $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 to 17.2 mg, with the same 45-day condition at the top two doses); Mounjaro $499 at every strength. Our cost guide covers list prices, savings cards and Medicare.

Which one, and who decides

That is a prescribing decision. The labels give the shape of it: Zepbound and Wegovy HD have the largest label results; the pills avoid injections and Foundayo has no food or water rules; Ozempic and Mounjaro are diabetes drugs that some clinicians prescribe off-label. Insurance often decides more than preference does. Whichever it is, the drug should come from a licensed prescriber and a pharmacy you can look up; our guide to how online prescribing works explains what to check.

When to talk with a clinician

Before starting any of these, and especially if you have thyroid cancer in the family, a history of pancreatitis or gallbladder disease, take insulin or a sulfonylurea, or are pregnant or planning to be. If you are switching between products, the labels warn against using two GLP-1 products at once.

Frequently asked questions

Which GLP-1 works best for weight loss?

By label result, Zepbound 15 mg (20.9% at 72 weeks) and Wegovy HD 7.2 mg (18.8%). The trials were not head to head, and individual response varies; a clinician weighs tolerability, other conditions and coverage.

Is Ozempic approved for weight loss?

No. Ozempic is approved for type 2 diabetes (with cardiovascular and kidney outcome indications). Wegovy is the semaglutide product approved for weight.

Is there a GLP-1 pill for weight loss?

Two: Wegovy tablets (semaglutide 25 mg, approved December 2025) and Foundayo (orforglipron, approved April 2026). Rybelsus and Ozempic tablets are diabetes products.

Is there a generic GLP-1?

Generic liraglutide: the FDA approved the first generic referencing Victoza in December 2024 and the first referencing Saxenda in August 2025. There is no generic semaglutide or tirzepatide; compounded versions are not generics.

18 sources

These are the sources this guide cites, with each source's date where it publishes one. How we source.

Read next

Is Wegovy approved for fatty liver (MASH)? What the label covers and who qualifies

Yes, for one stage of disease. The FDA approved Wegovy injection on August 15, 2025, under accelerated approval, for adults with noncirrhotic MASH and F2 to F3 liver fibrosis, alongside diet and exercise. Cirrhosis, milder fatty liver, children and Wegovy tablets are outside the label. In ESSENCE, steatohepatitis resolved in 63 percent on Wegovy against 34 percent on placebo at 72 weeks; the confirmatory outcome trial is scheduled to finish in 2029.

Continue reading

Medical Disclaimer

This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.

Newsletter

One email a week: what changed, what it costs, what to do. Every item sourced and dated.

You're on the list. Look for your first issue next week.

No spam. Unsubscribe anytime.

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.

Related Articles

More from Michael Reeves

More in Weight and metabolism